This PhD project is embedded within a broader research program aiming to overcome chemoresistance in acute myeloid leukemia (AML), a major cause of early relapse and treatment failure. The candidate will explore the molecular and cellular mechanisms that allow residual leukemia cells to survive therapeutic
stress, focusing on metabolic adaptations and translational regulation. The project will involve cutting-edge techniques and functional assays to characterize novel vulnerabilities in chemoresistant AML. Through these approaches, the candidate will contribute to the identification and validation of innovative therapeutic targets designed to disrupt leukemia cell survival pathways. The ultimate goal of this project is to advance therapies addressing a critical unmet clinical need in leukemia treatment.
